Sionna Therapeutics, Inc. (SION)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$3.73+2.19%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · SION
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -42.6% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name operates in a high-miss-rate industry and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers · Company calendar date is not available
SION — officer change
Dated 2026-09-14
Chief Business Officer — Caroline Stark Beer: The Chief Business Officer was terminated without cause as part of a restructuring, representing a genuine loss of a senior executive.
Why it matters: The Phase 1 drug pair met its safety and drug-level goals. The new trial will test the pair in adults with CF.
Worry ifThe trial reports a serious safety issue or drug levels below the planned range.
Less concerning ifThe trial reports no serious safety issue and drug levels within the planned range.
Why it matters: Sweat chloride is a key measure of CFTR function. A clear drop would support the new drug pair; no drop would weaken that case.
Watch forAfter 28 days, the trial reports a clear mean drop in sweat chloride from baseline.
Also watch forAfter 28 days, the trial reports no mean drop in sweat chloride from baseline.
Why it matters: Sionna is loss-making and has cut staff to lower costs. The next report can show whether spending is moving down.
Worry ifThe November 4 update says operating costs fell below $32.5 million from the prior quarter.
Less concerning ifThe November 4 update says operating costs were $32.5 million or more.
Why it matters: The trial is the next test of SION-451 plus SION-2222 in people with CF. A delay would push back the first proof-of-concept test.
Supportive ifThe AscenSION CF trial starts by March 31, 2027, as planned.
Worry ifThe trial has not started by March 31, 2027, or the company reports a delay.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$327 on $10,000 · ±3.3% | How much price usually moves either way. |
| Bad day | $842 loss on $10,000 · 8.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,295 loss on $10,000 · 93.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Sionna plans to fund work into the second half of 2029. Cash and staff changes will test that plan.
Worry ifA company update keeps the cash runway in the second half of 2029 and reports lower costs.
Less concerning ifA company update moves the runway to before the second half of 2029 or reports higher costs.